This page contains a Flash digital edition of a book.


Disease research facilitated by data analysis solution

The Germans Trias i Pujol Foundation (IGPT) will use sophisticated data analysis from Qlucore to gain greater insight into the causes and treatment of human disease. Researchers at the Health Sciences

Research Institute of the IGTP will be using Qlucore Omics Explorer to support their research into various diseases, including infl ammatory bowel disease, Crohn’s disease, ulcerative colitis and more. The IGTP has an international reputation for its high-profi le research

activities in areas that include colon cancer, infl ammatory bowel diseases, hepatocarcinoma, surgical techniques, microbiology, neurology and basic research. By focusing on these key areas, the IGTP hopes to generate, preserve, disseminate and increase multidisciplinary and translational knowledge in all of these areas, and to support the continued technological development in biomedical sciences. ‘Our aim at the IGTP is to become a research centre of reference, so that we can take all of the knowledge


LIMS provider GenoLogics has secured an $8m round of strategic fi nancing led by investor Illumina, a provider of next-generation sequencing (NGS) instruments. The fi nancing will be used to accelerate product development for future clinical applications and new desktop sequencing systems, and to expand sales and marketing functions. Illumina senior vice president and chief commercial offi cer Tristan Orpin will also be joining GenoLogics’ board of directors. ‘This strategic investment in GenoLogics will benefi t our

mutual sequencing customers,’ said Orpin. ‘We value the unique data management capabilities GenoLogics brings to our customers and the industry.’ GenoLogics and Illumina entered into a worldwide co-selling agreement for its LIMS earlier this year. In September, GenoLogics released the LIMS preconfi gured package for Illumina NGS. The GenoLogics LIMS preconfi gured package for Illumina NGS allows labs to move into production more quickly by incorporating de facto standards and best practices for

NGS implementations. ‘The strategic investment by Illumina illustrates our companies’ collective commitment to helping our customers overcome some of the most challenging barriers to next-generation sequencing adoption, namely data management,’ GenoLogics CEO Michael Ball said. ‘Illumina provides important insights to these challenges and we look forward to working jointly with them as we expand our line of innovative, best-in-class LIMS products for next-generation genomics.’

Genedata licences data management platform to MorphoSys

MorphoSys will license Genedata Biologics as its R&D data management platform, to support the former’s internal and partner- based biologics discovery programs for lead fi nding and optimisation. Genedata Biologics integrates with the MorphoSys laboratory infrastructure and interacts with discovery technologies, including the MorphoSys HUCAL antibody library,


screening, and expression platforms. ‘Therapeutic antibodies are one of the fastest-growing drug classes in human healthcare,’ said Dr Markus Enzelberger, vice president and head of discovery alliances and technologies at MorphoSys. ‘To advance our leadership in this fi eld, our biopharma R&D operations require an integrated and scalable informatics infrastructure that can

be tailored to support our biologics discovery processes. Genedata Biologics provides comprehensive biologics data management functionality and the fl exibility needed to support our proprietary antibody discovery processes and technology portfolio. And, it provides this functionality out of the box, which saves valuable research time and money.’

that we generate here and transfer it to clinical practice and therapeutic centres all over the world,’ says Eli Pedrosa Tapias PhD, technical supervisor at the IGPT. ‘Tools like Qlucore Omics Explorer are helping us to achieve this goal by making our research much more effi cient, and by providing our researchers with valuable data that they can interpret very quickly. We can afford to be more creative with our theories, and gain much greater insight into the mysteries of human disease.’


Accelrys has signed an agreement with Scynexis to sell the latter’s Hit Explorer Operating System (HEOS) for comprehensive drug discovery information management. Agilent Technologies and Ambry Genetics have signed an agreement under which Ambry Genetics will use the Agilent SureSelect Target Enrichment System for exome sequencing services. CLC Bio and Biobase have launched a plug-in for the former’s new framework for visualising, combining and analysing genome data, Genome Gateway, which integrates the human-curated biological databases contained in Biobase’s Genome Trax.

Epigenetics centre selects LIMS for research

The Center for Epigenetics at Johns Hopkins has selected Exemplar LIMS from Sapio Sciences as its LIMS and ELN solution.

Sapio was chosen because of Exemplar’s ability to manage a diversity of data from different domains and for its ability to implement workfl ows/processes rapidly. The Center for Epigenetics will be utilising Exemplar LIMS capabilities for sample management, electronic lab notebooks as part of its epigenetic studies. In particular, Exemplar LIMS will manage the Illumina HiSeq and Illumina Infi nium platform workfl ows.

Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40